Cell-free DNA: Treasure trove for cancer medicine by Tanic, M & Beck, S
Circulating DNA: an information treasure trove for cancer medicine 
 
Fragments of DNA that are derived from dead tumour cells and shed into a patient’s blood have been 
utilised as biomarkers for the diagnosis and prognosis of liver cancer. 
 
Miljana Tanić and Stephan Beck 
 
Successful cancer treatment is dependent on many factors, including the correct identification of the 
type of cancer (diagnosis) and an accurate prediction of its likely course (prognosis). A number of 
biomarkers are widely used for the diagnosis of cancers today. However, identifying and employing 
the most accurate biomarker has proven difficult, particularly for cancer detection. In this issue of 
Nature Materials [1] the group led by Kang Zhang compared the epigenetic profiles of normal versus 
cancer circulating tumour DNA to select and validate biomarkers for the diagnosis and prognosis of 
hepatocellular carcinoma (HCC).  
 
Both healthy and cancer cells release genomic DNA (gDNA) into the blood stream during cell death 
through apoptosis or necrosis, or by active secretion in the form of short cell-free DNA (cfDNA) 
fragments [2]. In cancer patients, only a small proportion of the total cfDNA is derived from the tumour 
and referred to as circulating tumour DNA (ctDNA). From a clinical perspective, this allows tumour 
DNA from anywhere in a patient’s body to be detected and monitored as ctDNA in the plasma 
obtained from peripheral blood though a minimally invasive blood draw or liquid biopsy [3]. Despite 
their sparseness, ctDNAs have been detected for a variety of cancers even at an early stage of the 
disease progression [4]. However, such a diagnostic procedure is not without challenges due to minute 
amounts of ctDNA, particularly if the analysis involves epigenetic changes [5]. Epigenetic changes refer 
to chemical modifications (such as DNA methylation) of the genome and its functional configuration 
(chromatin). Collectively, epigenetic modifications confer the required plasticity for cellular 
differentiation which, when deregulated in cancer, becomes one of its major hallmarks [6]. Although 
ctDNA carries the relevant genetic as well as epigenetic information, simultaneous detection of 
genome-wide DNA methylation marks in cfDNA has been limited by the requirement of large amounts 
of starting material for target capture. 
 
In their latest research, Xu et al. demonstrated the power of targeted bisulfite sequencing for the 
detection of ctDNA methylation markers for the diagnosis and prognosis of HCC in a cohort of 1098 
HCC patients and 885 healthy control subjects. They initially screened approximately 450,000 cytosine 
guanine dinucleotide sites (CpGs) across the genome for differentially methylated positions (DMPs) 
between HCC tumour DNAs (tDNAs) from The Cancer Genome Atlas and gDNAs derived from blood 
samples of heathy controls (Figure 1). They then designed capture probes for the top 1,000 DMPs, of 
which less than half were successfully amplified and further tested in matched sets of tDNA, gDNA 
and ctDNA from patients and healthy controls. Identification of blocks of co-methylated CpGs allowed 
the authors to further refine the panel. Finally, they used machine learning algorithms to extract a 
panel of 10 DMPs that were capable of discriminating between HCC and healthy controls as well as 
potentially confounding indications such as viral infection, cirrhosis and fatty liver. The resulting 
combined diagnostic score (cd-score) compared favourably to that achieved by current clinical 
practice using alpha-fetoprotein (AFP) as a biomarker and reached a validated sensitivity of 90.5% and 
specificity of 83.2%. This indicates that the cd-score based test is suitable for the diagnosis of HCC 
using liquid biopsies and was successfully assessed for predicting tumour load, treatment response 
and HCC staging. In a parallel approach, the authors also established a combined prognostic score (cp-
score) based on a different set of 8 DMPs and a comprehensive survival analysis. The resulting 
validated cp-score based test was able to predict high versus low prognostic risk independently of 
other factors and, again, was superior to the current clinical practice using AFP.  
 
Diagnosis of cancer is challenging due to the heterogeneity of the disease in terms of identification of 
accurate biomarkers for a specific cancer type. As we move into an era of personalised and precision 
medicine which involves deep and multi-omic profiling of each cancer patient, this current limitation 
can be addressed through large data sets and more advanced machine and deep learning algorithms, 
presuming there is a will among all concerned to share the required information more openly than is 
currently practised [7]. As the current study has successfully demonstrated, the combination of a 
range of platforms is inevitably essential for more precise and informed diagnosis of cancers. A recent 
study utilised a combination of conventional tumour DNA assays, bioinformatics tools, as well as 
cognitive computational systems, for the analysis of deep cancer genomic datasets to identify 
actionable variants and therapeutic options in a clinically timely manner for individual patients [8].  
 
Despite of the limitations of these studies, such as the need for longer-term patient surveillance, they 
take a major step forward in highlighting the progress of cancer diagnosis, predicting prognosis and 
identifying patients that would likely require aggressive therapeutic options. With our aging 
populations comes the dramatic increase in the incidence of cancer. According to Cancer Research 
UK, one in two individuals will develop cancer at some point in their lives [9].  However, the use of 
biomarkers such as ctDNA methylation markers and prediction of prognosis, the goal of defeating 
cancer, or at least turning it into a treatable disease through early detection is evidently coming within 
reach. 
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Figure 1: Study design and innovations. The upper panel shows different types of DNA (genomic DNA (gDNA) 
tumour DNA (tDNA), cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA)) that were analysed using 450K 
profiling and/or target bisulfite sequencing (BS-seq). The lower panel shows the innovative use of machine learning 
algorithms (depicted by the brain-in-a-chip icon) for the identification of 10 and 8 DNA methylation biomarkers 
(depicted as 5-methylcytosines) for HCC diagnosis and prognosis, respectively.  
 
 
 
 
 
 
 
